Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Epanutin

- PMLiVE

Pfizer’s Talzenna combination receives FDA approval for metastatic prostate cancer

Up to 20% of patients develop metastatic prostate cancer within five to seven years of diagnosis

- PMLiVE

Pfizer reports positive results for elranatamab in multiple myeloma

An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

- PMLiVE

Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections

AMR has been declared by WHO as one of the top ten threats to global health

- PMLiVE

Pfizer’s RSV vaccine approved by FDA for older adults

RSV infections in older adults account for up to 160,000 hospitalisations each year in the US

- PMLiVE

COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP

Pfizer’s oral antiviral was granted accelerated approval in the US in December 2021

- PMLiVE

NHS to introduce world-first genetic blood-matching test for transfusion treatments

NHS Blood and Transplant will receive almost £1m in funding from NHS England

- PMLiVE

Pfizer’s maternal RSV vaccine candidate backed by FDA advisory committee

Up to 80,000 children aged under five are hospitalised each year in the US due to RSV infection

- PMLiVE

Pfizer’s next-generation pneumococcal vaccine granted FDA approval

The vaccine can help protect against 20 serotypes of the streptococcus pneumoniae bacteria

- PMLiVE

NHS spring COVID-19 booster programme opens up for those at highest risk

Around five million people are eligible for the booster in line with the JCVI’s advice

- PMLiVE

Authorisation for Moderna and Pfizer/BioNTech’s bivalent COVID-19 vaccines simplified by FDA

The vaccines are now authorised for all doses in individuals aged six months and older

The ongoing evolution of Medical Affairs

In the latest episode of Impetus Digital's Fireside Chat series, Natalie Yeadon, Co-Founder and CEO of Impetus Digital talks to Eddie Power, Vice President of North America Medical Affairs, Hospital...

Impetus Digital

- PMLiVE

Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study

The treatment is already approved in the US for three disease states of prostate cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links